SRSF2 is essential for hematopoiesis, and its myelodysplastic syndrome-related mutations dysregulate alternative Pre-mRNA splicing

Molecular and Cellular Biology

Volumn 35, Issue 17, 2015, Pages 3071-3082

  Komeno, Yukiko ^a   Huang, Yi Jou ^b   Qiu, Jinsong ^c   Lin, Leo ^b   Xu, YiJun ^b   Zhou, Yu ^c   Chen, Liang ^c   Monterroza, Dora D ^b   Li, Hairi ^c   DeKelver, Russell C ^b   Yan, Ming ^a   Fu, Xiang Dong ^a,c   Zhang, Dong Er ^a,b,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTIDINE DERIVATIVE; POLYINOSINIC POLYCYTIDYLIC ACID; PROLINE 95 HISTIDINE; SERINE ARGININE RICH PROTEIN; SRSF2 PROTEIN; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN; NUCLEAR PROTEIN; RIBONUCLEOPROTEIN; RNA PRECURSOR; SFRS2 PROTEIN, MOUSE; SMALL INTERFERING RNA;

ADULT; ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ERYTHROBLAST; FETUS LIVER; FLOW CYTOMETRY; GENE DELETION; GENE MUTATION; GRANULOCYTE; HEMATOPOIESIS; HEMATOPOIETIC SYSTEM; IN VITRO STUDY; MISSENSE MUTATION; MOUSE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; BLOOD CELL; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL LINE; CELL SURVIVAL; CYTOLOGY; GENETICS; HEK293 CELL LINE; HEMATOPOIETIC STEM CELL; HUMAN; KNOCKOUT MOUSE; LIVER; METABOLISM; MUTATION; PATHOLOGY; RNA INTERFERENCE; RNA SPLICING;

MUS;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BLOOD CELLS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL LINE; CELL SURVIVAL; HEK293 CELLS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; POLY I-C; RIBONUCLEOPROTEINS; RNA INTERFERENCE; RNA PRECURSORS; RNA SPLICING; RNA, SMALL INTERFERING;

EID: 84938881673     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00202-15     Document Type: Article

References (49)

1. Ades L, Itzykson R, Fenaux P. 20 March 2014, posting date. Myelodysplastic syndromes. Lancet http://dx.doi.org/10.1016/S0140-6736(13)61901-7.
2. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M. 2013. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122:2943-2964. http://dx.doi.org/10.1182/blood-2013-03-492884.
3. Kulasekararaj AG, Mohamedali AM, Mufti GJ. 2013. Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes. Br J Haematol 162:587-605. http://dx.doi.org/10.1111/bjh.12435.
4. Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C, Miller CA, Niu B, McLellan MD, Dees ND, Fulton R, Elliot K, Heath S, Grillot M, Westervelt P, Link DC, DiPersio JF, Mardis E, Ley TJ, Wilson RK, Graubert TA. 2013. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 27:1275-1282. http://dx.doi.org/10.1038/leu.2013.58.
5. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. 2011. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496-2506. http://dx.doi.org/10.1056/NEJMoa1013343.
6. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, Chalkidis G, Suzuki Y, Shiosaka M, Kawahata R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Ishiyama K, Mori H, Nolte F, Hofmann WK, Miyawaki S, Sugano S, Haferlach C, Koeffler HP, Shih LY, Haferlach T, Chiba S, Nakauchi H, Miyano S, Ogawa S. 2011. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64-69. http://dx.doi.org/10.1038/nature10496.
7. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, Krysiak K, Harris CC, Koboldt DC, Larson DE, McLellan MD, Dooling DJ, Abbott RM, Fulton RS, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Grillot M, Baty J, Heath S, Frater JL, Nasim T, Link DC, Tomasson MH, Westervelt P, DiPersio JF, Mardis ER, Ley TJ, Wilson RK, Walter MJ. 2012. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 44:53-57.
8. Yoshida K, Ogawa S. 2014. Splicing factor mutations and cancer. Wiley Interdiscip Rev RNA 5:445-459. http://dx.doi.org/10.1002/wrna.1222.
9. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Rapado I, Cvejic A, Rance R, McGee C, Ellis P, Mudie LJ, Stephens PJ, McLaren S, Massie CE, Tarpey PS, Varela I, Nik-Zainal S, Davies HR, Shlien A, Jones D, Raine K, Hinton J, Butler AP, Teague JW, Baxter EJ, Score J, Galli A, Della Porta MG, Travaglino E, Groves M, Tauro S, Munshi NC, Anderson KC, El-Naggar A, Fischer A, Mustonen V, Warren AJ, Cross NC, Green AR, Futreal PA, Stratton MR, Campbell PJ. 2011. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. NEngl J Med 365:1384-1395. http://dx.doi.org/10.1056/NEJMoa1103283.
10. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A, O'Keefe C, Rogers HJ, Sekeres MA, Maciejewski JP, Tiu RV. 2012. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 26:542-545. http://dx.doi.org/10.1038/leu.2011.232.
11. Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, Hricik T, Heguy A, Hedvat C, Gonen M, Kantarjian H, Levine RL, Abdel-Wahab O, Verstovsek S. 2012. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 119:4480-4485. http://dx.doi.org/10.1182/blood-2011-11-390252.
12. Damm F, Nguyen-Khac F, Fontenay M, Bernard OA. 2012. Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies. Leukemia 26:2027-2031. http://dx.doi.org/10.1038/leu.2012.86.
13. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, Ramsay AJ, Bea S, Pinyol M, Martinez-Trillos A, Lopez-Guerra M, Colomer D, Navarro A, Baumann T, Aymerich M, Rozman M, Delgado J, Gine E, Hernandez JM, Gonzalez-Diaz M, Puente DA, Velasco G, Freije JM, Tubio JM, Royo R, Gelpi JL, Orozco M, Pisano DG, Zamora J, Vazquez M, Valencia A, Himmelbauer H, Bayes M, Heath S, Gut M, Gut I, Estivill X, Lopez-Guillermo A, Puente XS, Campo E, Lopez-Otin C. 2012. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 44:47-52. http://dx.doi.org/10.1038/ng.1032.
14. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, Fangazio M, Vaisitti T, Monti S, Chiaretti S, Guarini A, Del Giudice I, Cerri M, Cresta S, Deambrogi C, Gargiulo E, Gattei V, Forconi F, Bertoni F, Deaglio S, Rabadan R, Pasqualucci L, Foa R, Dalla-Favera R, Gaidano G. 2011. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 118:6904-6908. http://dx.doi.org/10.1182/blood -2011-08-373159.
15. Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S, Haldemann B, Fries T, Kronke J, Kuhn MW, Paschka P, Kayser S, Wolf S, Gaidzik VI, Schlenk RF, Rucker FG, Dohner H, Lottaz C, Dohner K, Bullinger L. 2012. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood 120:e83-e92. http://dx.doi.org/10.1182/blood-2011-12-401471.
16. Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J, Wlodarski MW, Kolking B, Wichmann M, Gorlich K, Gohring G, Bug G, Ottmann O, Niemeyer CM, Hofmann WK, Schlegelberger B, Ganser A, Heuser M. 2012. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 119:3578-3584. http://dx.doi.org/10.1182/blood-2011-12-399337.
17. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, Shlien A, Groves MJ, Forbes SA, Raine K, Hinton J, Mudie LJ, McLaren S, Hardy C, Latimer C, Della Porta MG, O'Meara S, Ambaglio I, Galli A, Butler AP, Walldin G, Teague JW, Quek L, Sternberg A, Gambacorti-Passerini C, Cross NC, Green AR, Boultwood J, Vyas P, Hellstrom-Lindberg E, Bowen D, Cazzola M, Stratton MR, Campbell PJ. 2013. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122:3616-3627, quiz 3699. http://dx.doi.org/10.1182/blood-2013-08-518886.
18. Hirabayashi S, Flotho C, Moetter J, Heuser M, Hasle H, Gruhn B, Klingebiel T, Thol F, Schlegelberger B, Baumann I, Strahm B, Stary J, Locatelli F, Zecca M, Bergstraesser E, Dworzak M, van den Heuvel-Eibrink MM, De Moerloose B, Ogawa S, Niemeyer CM, Wlodarski MW. 2012. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood 119:e96-e99. http://dx.doi.org/10.1182/blood-2011-12-395087.
19. Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A, Przychodzen B, Bupathi M, Guinta K, Afable MG, Sekeres MA, Padgett RA, Tiu RV, Maciejewski JP. 2012. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 119:3203-3210. http://dx.doi.org/10.1182/blood-2011-12-399774.
20. Wu SJ, Kuo YY, Hou HA, Li LY, Tseng MH, Huang CF, Lee FY, Liu MC, Liu CW, Lin CT, Chen CY, Chou WC, Yao M, Huang SY, Ko BS, Tang JL, Tsay W, Tien HF. 2012. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood 120:3106-3111. http://dx.doi.org/10.1182/blood-2012-02-412296.
21. Zhou Z, Fu XD. 2013. Regulation of splicing by SR proteins and SR protein-specific kinases. Chromosoma 122:191-207. http://dx.doi.org/10.1007/s00412-013-0407-z.
22. Ding JH, Xu X, Yang D, Chu PH, Dalton ND, Ye Z, Yeakley JM, Cheng H, Xiao RP, Ross J, Chen J, Fu XD. 2004. Dilated cardiomyopathy caused by tissue-specific ablation of SC35 in the heart. EMBO J 23:885-896. http://dx.doi.org/10.1038/sj.emboj.7600054.
23. Xiao R, Sun Y, Ding JH, Lin S, Rose DW, Rosenfeld MG, Fu XD, Li X. 2007. Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis. Mol Cell Biol 27:5393-5402. http://dx.doi.org/10.1128/MCB.00288-07.
24. Wang HY, Xu X, Ding JH, Bermingham JR, Jr, Fu XD. 2001. SC35 plays a role in T cell development and alternative splicing of CD45. Mol Cell 7:331-342. http://dx.doi.org/10.1016/S1097-2765(01)00181-2.
25. Li H, Qiu J, Fu XD. 2012. RASL-seq for massively parallel and quantitative analysis of gene expression. Curr Protoc Mol Biol Chapter 4:4.13.1-4.13.9. http://dx.doi.org/10.1002/0471142727.mb0413s98.
26. Zhou Z, Qiu J, Liu W, Zhou Y, Plocinik RM, Li H, Hu Q, Ghosh G, Adams JA, Rosenfeld MG, Fu XD. 2012. The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol Cell 47:422-433. http://dx.doi.org/10.1016/j.molcel.2012.05.014.
27. Komeno Y, Yan M, Matsuura S, Lam K, Lo MC, Huang YJ, Tenen DG, Downing JR, Zhang DE. 25 April 2014, posting date. Runx1 exon 6-related alternative splicing isoforms differentially regulate hematopoiesis in mice. Blood http://dx.doi.org/10.1182/blood-2013-08-521252.
28. Matsuoka A, Tochigi A, Kishimoto M, Nakahara T, Kondo T, Tsujioka T, Tasaka T, Tohyama Y, Tohyama K. 2010. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia 24:748-755. http://dx.doi.org/10.1038/leu.2009.296.
29. Drexler HG, Dirks WG, Macleod RA. 2009. Many are called MDS cell lines: one is chosen. Leuk Res 33:1011-1016. http://dx.doi.org/10.1016/j.leukres.2009.03.005.
30. Toba K, Winton EF, Koike T, Shibata A. 1995. Simultaneous three-color analysis of the surface phenotype and DNA-RNA quantitation using 7-amino-actinomycin D and pyronin Y. J Immunol Methods 182:193-207. http://dx.doi.org/10.1016/0022-1759(95)00050-K.
31. de Boer J, Williams A, Skavdis G, Harker N, Coles M, Tolaini M, Norton T, Williams K, Roderick K, Potocnik AJ, Kioussis D. 2003. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur J Immunol 33:314-325. http://dx.doi.org/10.1002/immu.200310005.
32. Iwasaki H, Somoza C, Shigematsu H, Duprez EA, Iwasaki-Arai J, Mizuno S, Arinobu Y, Geary K, Zhang P, Dayaram T, Fenyus ML, Elf S, Chan S, Kastner P, Huettner CS, Murray R, Tenen DG, Akashi K. 2005. Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood 106:1590-1600. http://dx.doi.org/10.1182/blood-2005-03-0860.
33. Sun W, Downing JR. 2004. Haploinsufficiency of AML1 results in a decrease in the number of LTR-HSCs while simultaneously inducing an increase in more mature progenitors. Blood 104:3565-3572. http://dx.doi.org/10.1182/blood-2003-12-4349.
34. Cong X, Yan M, Yin X, Zhang DE. 2010. Hematopoietic cells from Ube1L-deficient mice exhibit an impaired proliferation defect under the stress of bone marrow transplantation. Blood Cells Mol Dis 45:103-111. http://dx.doi.org/10.1016/j.bcmd.2010.05.009.
35. Lopato S, Kalyna M, Dorner S, Kobayashi R, Krainer AR, Barta A. 1999. atSRp30, one of two SF2/ASF-like proteins from Arabidopsis thaliana, regulates splicing of specific plant genes. Genes Dev 13:987-1001. http://dx.doi.org/10.1101/gad.13.8.987.
36. Kraus ME, Lis JT. 1994. The concentration of B52, an essential splicing factor and regulator of splice site choice in vitro, is critical for Drosophila development. Mol Cell Biol 14:5360-5370.
37. Labourier E, Bourbon HM, Gallouzi IE, Fostier M, Allemand E, Tazi J. 1999. Antagonism between RSF1 and SR proteins for both splice-site recognition in vitro and Drosophila development. Genes Dev 13:740-753. http://dx.doi.org/10.1101/gad.13.6.740.
38. Sureau A, Gattoni R, Dooghe Y, Stevenin J, Soret J. 2001. SC35 autoregulates its expression by promoting splicing events that destabilize its mRNAs. EMBO J 20:1785-1796. http://dx.doi.org/10.1093/emboj/20.7.1785.
39. Lareau LF, Inada M, Green RE, Wengrod JC, Brenner SE. 2007. Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements. Nature 446:926-929. http://dx.doi.org/10.1038/nature05676.
40. Ni JZ, Grate L, Donohue JP, Preston C, Nobida N, O'Brien G, Shiue L, Clark TA, Blume JE, Ares M, Jr. 2007. Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. Genes Dev 21:708-718. http://dx.doi.org/10.1101/gad.1525507.
41. Matsunawa M, Yamamoto R, Sanada M, Sato-Otsubo A, Shiozawa Y, Yoshida K, Otsu M, Shiraishi Y, Miyano S, Isono K, Koseki H, Nakauchi H, Ogawa S. 18 February 2014, posting date. Haploinsufficiency of Sf3b1 leads to compromised stem cell function but not to myelodysplasia. Leukemia http://dx.doi.org/10.1038/leu.2014.73.
42. Daubner GM, Clery A, Jayne S, Stevenin J, Allain FH. 2012. A syn-anti conformational difference allows SRSF2 to recognize guanines and cytosines equally well. EMBO J 31:162-174. http://dx.doi.org/10.1038/emboj.2011.367.
43. Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC, Ramakrishnan A, Li Y, Chung YR, Micol JB, Murphy ME, Cho H, Kim MK, Zebari AS, Aumann S, Park CY, Buonamici S, Smith PG, Deeg HJ, Lobry C, Aifantis I, Modis Y, Allain FH, Halene S, Bradley RK, Abdel-Wahab O. 2015. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27:617-630. http://dx.doi.org/10.1016/j.ccell.2015.04.006.
44. MacArthur MW, Thornton JM. 1991. Influence of proline residues on protein conformation. J Mol Biol 218:397-412. http://dx.doi.org/10.1016/0022-2836(91)90721-H.
45. Ozawa T, Okazaki K, Kitaura K. 2011. Importance of CH/pi hydrogen bonds in recognition of the core motif in proline-recognition domains: an ab initio fragment molecular orbital study. J Comput Chem 32:2774-2782. http://dx.doi.org/10.1002/jcc.21857.
46. Zhou T, Hasty P, Walter CA, Bishop AJ, Scott LM, Rebel VI. 2013. Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA? Exp Hematol 41:665-674. http://dx.doi.org/10.1016/j.exphem.2013.04.008.
47. Montecucco A, Biamonti G. 2013. Pre-mRNA processing factors meet the DNA damage response. Front Genet 4:102. http://dx.doi.org/10.3389/fgene.2013.00102.
48. Ji X, Zhou Y, Pandit S, Huang J, Li H, Lin CY, Xiao R, Burge CB, Fu XD. 2013. SR proteins collaborate with 7SK and promoter-associated nascent RNA to release paused polymerase. Cell 153:855-868. http://dx.doi.org/10.1016/j.cell.2013.04.028.
49. Mo S, Ji X, Fu XD. 2013. Unique role of SRSF2 in transcription activation and diverse functions of the SR and hnRNP proteins in gene expression regulation. Transcription 4:251-259. http://dx.doi.org/10.4161/trns.26932.